Shifting the lines against central nervous system disorders

« A disruptive technology, which can be applied in the treatment of numerous conditions »

> Press releases

THERANEXUS reports cash position as of September 30th 2019

Download PDF File (285 Ko)

THERANEXUS announces its first half 2019 results

Download PDF File (285 Ko)

A new milestone reached for Theranexus: inclusion of last patient in phase II trial for THN102 in Parkinson’s patients

Download PDF File (285 Ko)

THERANEXUS announces inclusion of last subject in its phase 1b trial of THN201

Download PDF File (397 Ko)

THERANEXUS announces the publication of two scientific papers and a presentation at the European pain congress (EFIC) to be held on 3-7 September in Valencia, Spain

Download PDF File (393 Ko)

THERANEXUS raises approximately 2.2 million euros in a placement reserved to a category of persons 

Dowload PDF File (615 Ko)

THERANEXUS announces the launch of a capital increase by private placement for a maximum amount of euro 4 million

Download PDF File (284 Ko)

THERANEXUS reports cash position as of June 30th 2019

Download PDF File (268 Ko)

Theranexus and Beyond Batten Disease Foundation (BBDF) announce agreement in
principle to develop and market Batten disease drug candidate BBDF 101

Download PDF File (416 Ko)

THERANEXUS invited to join in the HealthTech Investor Days (HTDI) 24 & 25 June in Paris

Download PDF File (363 Ko)